<DOC>
	<DOCNO>NCT00257322</DOCNO>
	<brief_summary>While new treatment metastatic recurrent colorectal cancer become available past several year , disease remain incurable limited life expectancy time diagnosis . New strategy treatment disseminate colorectal cancer need . Under proposal , patient advance colorectal cancer receive Granulocyte-Macrophage Colony-Stimulating Factor ( GM-CSF ) stimulate endogenous dendritic cell enhance anti-tumor immune mechanism . This combined standard chemotherapy patient follow response overall survival . Detailed correlative laboratory analysis also perform define extent dendritic cell cellular immune system stimulation .</brief_summary>
	<brief_title>Cellular Immune Augmentation Colon Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>Patient must : metastatic , disseminated recurrent colon rectal cancer Patient receive weekly biweekly chemotherapy least 4 cycle ( 4 week ) Examples include : 5FU 5FU/leucovorin give weekly Irinotecan ( single agent ) give weekly 5FU/leucovorin/irinotecan give weekly Patient must able taught administer GMCSF subcutaneously Exclusion criterion : Known allergic adverse reaction GMCSF Chemotherapy administration frequently biweekly Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Metastatic colon cancer</keyword>
	<keyword>Metastatic rectal cancer</keyword>
</DOC>